Researchers at the University of Queensland are developing a clinical trial for remote neuromodulation

The Queensland Brain Institute under the University of Queensland has established a remote care center for the monitoring and management of patients with neurological disorders.


Founded in partnership with Neurosciences Queensland and Abbott Neuromodulation, the digital platform can remotely monitor patients and configure their equipment to manage and reduce their symptoms in real time. Patients are first placed with electrodes by stimulating electricity delivered through a pacemaker to alter the function of the brain to provide therapeutic assistance.

In a study, where the findings were published in a journal reviewed by fellow Nature Scientific Reports, the researchers focused on the platform’s safety, security, usability and usefulness, and improving its features with the use of patient intentions.

At the time of the market’s release of the deadline, the platform maintained a high index score after driving around 858 remote control times.

The medical center for remote neuromodulation systems has received approval from the Australian government and was established last year. It has a CE certification in Europe and has been certified by the US Food and Drug Administration.

Why it is

The disease has seen an increase in the demand for remote care facilities, especially for the elderly and those living in remote areas. Professor QBI Peter Silburn found that many people “wanted to change” the fields to remotely connect them to health care organizations.

Through their redesigned remote care program, patients with neurological disorders no longer need to personally see their doctors to manage their pain.

Moving forward, the Silburn team sees a widespread use of their digital health platform for health conditions. “As we learn more about biomarkers in brain disorders, we will clean up neuromodulation systems to improve the management of neuropsychiatric disorders such as depression, obsessive-compulsive disorder. , anorexia, and Tourette’s syndrome, to name a few, ”he said.


Last year, Abbott introduced a new feature to its neuromodulation therapy platform NeuroSphere that allows patients to receive treatments from their provider. US FDA approved The NeuroSphere Virtual Clinic enables a secure relationship between the patient and their physician using the associated clinician programmer app. The feature is available in the Abbott patient controller app on iOS devices.

It is a competitive neurostimulator NeuroPace went public in April last year. The company’s RNS system directly guides the cause of seizures in the brain. It collects EEG data via a wireless home phone that is shared with a doctor via a website.

Related Posts

Leave a Reply

Your email address will not be published.